Arrowhead Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

78.95 0.22

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

76.67

Maximum

80.73

Fő mutatók

By Trading Economics

Bevétel

-161M

-133M

Értékesítés

-190M

74M

P/E

Szektor átlag

47.744

50.958

Egy részvényre jutó nyereség

-0.93

Profit margin

-180.007

Munkavállalók

711

EBITDA

-165M

-107M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+13.13% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

853M

12B

Előző nyitás

78.73

Előző zárás

78.95

Hangulat hírek alapján

By Acuity

18%

82%

18 / 342 Rangsor szerint Healthcare

Arrowhead Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jún. 27. 00:02 UTC

ETF Constituents
News

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading amid geopolitical tensions and mixed U.S. equity performance, supported by gains from major companies.

2026. jún. 27. 00:02 UTC

Social Media
News

Fox Corp shares are lower in after-hours trading, amid discussions on FIFA World Cup viewership and a proposed merger raising regulatory concerns.

2026. jún. 27. 00:02 UTC

News

Fox Corp shares are lower in after-market hours, reflecting a decline from Friday's close despite increased soccer viewership during the FIFA World Cup.

2026. jún. 26. 23:51 UTC

News

iShares 20+ Year Treasury Bond ETF declines in after-market trading amid heightened geopolitical tensions from military actions in the Middle East.

2026. jún. 26. 23:41 UTC

News

Charter Communications is in talks with SpaceX for a partnership to enhance mobile services using Starlink, with shares trading higher in after-market hours.

2026. jún. 26. 23:31 UTC

Social Media
News

Barclays raised its price target for Micron Technology, citing strong earnings and AI demand. Shares are higher in after-market trading alongside broader market gains.

2026. jún. 26. 23:26 UTC

Social Media
News
ETF Constituents

Invesco QQQ Trust gains in after-market trading as retail sentiment turns bullish, contrasting with declines in the broader market amid tech sell-off.

2026. jún. 26. 23:16 UTC

Social Media
News

Amazon's stock rises after AWS announces a notable price increase in Nvidia compute services. Wells Fargo maintains a Buy rating and sets a target of $312.

2026. jún. 26. 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

2026. jún. 26. 23:02 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, supported by gains from top holdings and the Dow's third consecutive weekly increase.

2026. jún. 26. 23:02 UTC

Social Media
ETF Constituents
News

SPDR S&P 500 ETF Trust rises in after-market trading following S&P's affirmation of U.S. sovereign ratings, reflecting positive economic growth expectations.

2026. jún. 26. 23:02 UTC

Social Media
News

The United States Oil Fund LP rose after military strikes in the Strait of Hormuz heightened concerns over oil supply stability and increased trading activity.

2026. jún. 26. 23:02 UTC

Social Media
News

Fox Corp shares are trading lower in after-market hours, despite strong preliminary viewership for the USA vs. Turkiye World Cup match and merger discussions.

2026. jún. 26. 23:01 UTC

News

Fox Corp shares are lower in after-market trading amid broader market concerns over inflation and weakening momentum in AI-driven stocks, despite strong viewership for FIFA matches.

2026. jún. 26. 20:15 UTC

News
Correlated Moves
ETF Constituents

Vanguard Large-Cap ETF trades lower in after-market hours, reflecting declines in major holdings and a drop in the S&P 500 Index.

2026. jún. 26. 20:07 UTC

Correlated Moves
News
Macro Event

Bitcoin is higher today, reflecting a slight gain since Thursday's close. The Goods Trade Balance widened to a record deficit of $105.8 billion.

2026. jún. 26. 20:07 UTC

Macro Event
News
Correlated Moves

Bitcoin is higher during Friday's session, reflecting a slight gain since Thursday. Broader market sentiment appears to influence both Bitcoin and Ethereum.

2026. jún. 26. 20:06 UTC

Correlated Moves
News

The US dollar's decline pressures USD/SGD, which has traded lower since Thursday. Broader inflation concerns are influencing the asset's performance today.

2026. jún. 26. 20:06 UTC

News

The USD/NOK is higher today, supported by recent currency market dynamics. The US dollar declines amid falling oil prices and weak technology shares.

2026. jún. 26. 20:05 UTC

Social Media
News

Tesla Inc. shares are higher, supported by a report showing 15.78% revenue growth and strong EBITDA of $2.43 billion, exceeding industry averages.

2026. jún. 26. 20:05 UTC

Social Media
News
Correlated Moves

Shares of Alphabet Inc. are trading lower amid concerns about Waymo's impact on competitors, as noted in a recent BTIG analysis.

2026. jún. 26. 20:05 UTC

Social Media
News

Microsoft shares are higher amid a market rally, fueled by Michael Burry's bullish sentiment and a valuation surpassing $2.75 trillion.

2026. jún. 26. 20:04 UTC

News

Bank of America Securities reiterated its Buy rating on Ulta Beauty, setting a price target of $685 after a meeting with company executives. Shares are higher today.

2026. jún. 26. 20:03 UTC

News
Correlated Moves
Social Media

Intel Corp shares are declining as the semiconductor sector faces pressure. High trading volume reflects increased investor activity amid mixed social media sentiment.

2026. jún. 26. 20:02 UTC

News
Correlated Moves
Social Media

Applied Materials Inc shares are lower amid a decline in the Semiconductor Materials & Equipment sector, despite recent price target increases from analysts.

2026. jún. 26. 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, influencing economic perceptions. Vanguard Total Bond Market ETF is higher since Thursday's close.

2026. jún. 26. 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, potentially impacting economic perceptions and Federal Reserve interest rate decisions.

2026. jún. 26. 19:52 UTC

Correlated Moves
News
Social Media

Broadcom Inc shares fell to $370.12, a 10-week low, amid a broader downturn in the semiconductor sector and negative investor sentiment.

2026. jún. 26. 19:52 UTC

Social Media
News

Qualcomm Inc's stock is lower amid concerns over competition and supply shortages following its new chip architecture announcements for smartphones and data centers.

2026. jún. 26. 19:52 UTC

Social Media
News
Correlated Moves

NVIDIA Corp shares are declining as Amazon Web Services raises GPU prices, potentially reducing demand. Market focus shifts to memory stocks amid broader pressures.

Társak összehasonlítása

Árváltozás

Arrowhead Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

13.13% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 89.25 USD  13.13%

Magas 110 USD

Alacsony 46 USD

9 Wall Street elemző 12 hónapos célárain alapulva a(z)Arrowhead Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

9 ratings

8

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

18 / 342 Rangsor szerint Egészségügy

Hangulat hírek alapján

Nagyon erős bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat